Enalees conceives, manufactures and markets next-generation (LAMP technology), rapid molecular diagnostic tests for the veterinary sector.
At Genopole since 2016, the company has just written another page in its history at the biocluster.
On Thursday, 6 April, Enalees’s president Laurent Thiery, and its CEO Eric Germain, inaugurated their new proteomics development and production laboratory in the presence of Bertrand Gaume, prefect of Essonne, Stéphane Beaudet, president of Genopole and vice-president of the Ile-de-France Region, Michel Bisson, president of the Grand Paris Sud Urban Area, Frédéric Prost, president of Medef Essonne, and Patrick Rakotoson, president of the CCI Essonne.
A part of Enalees’s development plan, the new laboratory received a €500,000 grant in 2022 from the Île-de-France Region within the framework of the France 2030 Investments for the Future (PIA) program. Therein were:
- €300,000 to finance the acquisition of state of the art equipment
- and €105,000, partially financed by SEM Genopole, for the completion of the new laboratory, located close to the company’s current premises.
« Accompanying biocluster businesses at each phase of their development is one of Genopole’s pillars. We are delighted with this new accomplishment for Enalees and will continue to offer our help for the company’s future needs », declares David Bodet, deputy director of Genopole and GM of SEM Genopole.
To detect new pathogens…
To detect most notably twelve equine infectious diseases, including Lyme disease and equine influenza, the company deploys an isothermal amplification method. In France, 80% of equine veterinary clinics are equipped with it.
…the objective is to extend the range of tests.
The new laboratory will focus on producing new recombinant proteins specific to the detection of novel pathogenic agents present in infectious diseases and expanding the company’s reach beyond dogs, cats and horses.
Enalees plans to recruit a PhD and a qualified technician to accompany the lab’s launch.
With this new lab and in the medium term, Enalees may also be able to extend its service offer to third-party biotech and veterinary companies.
« CThis new proteomics development and pilot production lab is evidence of the strategic industrial evolution that we’ve nurtured at Enalees and our strong capacity for innovation, a explains Laurent Thiery. JI thank all of the partners who made this inauguration possible, notably the Île-de-France Region, the Essonne Department and Genopole, who work every day to advance the region’s flourishing capacity for innovation».
Speaking of Enalees
Bertrand Gaume, prefect of Essonne: « Through a range of accompaniment measures (PIA, etc.) as well as its own investment program, France takes pride in accompanying this Essonne prodigy since its creation at Genopole. I admire the human and societal values forwarded by Enalees but also the industrial project it’s developing in Essonne. The inauguration of their new lab is a good illustration of the company’s increasingly determined march toward industrialization. »
Valérie Pécresse, Presidente of the Ile-de-France Administrative Region: « Representing 40% of French research and 31% of France’s GDP, the prolificacy of the Île-de-France ecosystem is exceptional. The Region happily plays its role in the development of its disruptive businesses, from the seed of an idea through to the marketing of the resulting innovation. The Region’s aid attributed to Enalees, at Genopole since 2016, illustrates well this continuum of accompaniment in a high-potential market and we are very happy to see the company’s growing success, which creates value and employment for the territory ».
François Durovray, President of the Essonne Departmental Council: « I am very proud to see this Essonnian biotech gem pursue its expansion with the inauguration Thursday 6 April of its new proteomics development and production laboratory at Genopole, France’s leading biocluster located in Évry-Courcouronnes. Enalees is a 100% Essonnian company proposing an innovative service for veterinary diagnostics unique in France. Its development is a veritable asset for our territory and the company’s partners in France and throughout the world. It shows the department’s momentum and confirms its growing renown as a future-focused place where tomorrow’s technologies take wing. At Genopole as on the Saclay plateau, innovation is a cornerstone for Essonne’s identity, its engaged actors and its promising ecosystem. Today still, one thing is certain: we hope to see Enalees continue its pursuit of success. »
